Related references
Note: Only part of the references are listed.p53, cancer and the immune response
Julianne Blagih et al.
JOURNAL OF CELL SCIENCE (2020)
Targeting Mouse Double Minute 2: Current Concepts in DNA Damage Repair and Therapeutic Approaches in Cancer
Wen Li et al.
FRONTIERS IN PHARMACOLOGY (2020)
Milademetan, an oral MDM2 inhibitor, in well-differentiated/ dedifferentiated liposarcoma: results from a phase 1 study in patients with solid tumors or lymphomas
M.M. Gounder et al.
EUROPEAN JOURNAL OF CANCER (2020)
Evaluating dose-limiting toxicities of MDM2 inhibitors in patients with solid organ and hematologic malignancies: A systematic review of the literature
L. Pi et al.
LEUKEMIA RESEARCH (2019)
A phase I study of the HDM2 antagonist SAR405838 combined with the MEK inhibitor pimasertib in patients with advanced solid tumours
Vincent A. de Weger et al.
BRITISH JOURNAL OF CANCER (2019)
Phase 1b study of the MDM2 inhibitor AMG 232 with or without trametinib in relapsed/refractory acute myeloid leukemia
Harry P. Erba et al.
BLOOD ADVANCES (2019)
Reactivating TP53 signaling by the novel MDM2 inhibitor DS3032b as a therapeutic option for high-risk neuroblastoma
Viktor Arnhold et al.
ONCOTARGET (2018)
Dose and Schedule Determine Distinct Molecular Mechanisms Underlying the Efficacy of the p53-MDM2 Inhibitor HDM201
Sebastien Jeay et al.
CANCER RESEARCH (2018)
The development of piperidinones as potent MDM2-P53 protein - protein interaction inhibitors for cancer therapy
Guochao Liao et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2018)
A phase 1 study of MDM2 inhibitor DS-3032b in patients with well/de-differentiated liposarcoma (WD/DD LPS), solid tumors (ST) and lymphomas (L).
Todd Michael Bauer et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
MDM2/X inhibitors under clinical evaluation: perspectives for the management of hematological malignancies and pediatric cancer
Veronica Tisato et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2017)
Targeting the MDM2-p53 Protein-Protein Interaction for New Cancer Therapy: Progress and Challenges
Shaomeng Wang et al.
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE (2017)
The Cell-Cycle Arrest and Apoptotic Functions of p53 in Tumor Initiation and Progression
Jiandong Chen
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE (2016)
Clinical pharmacology characterization of RG7112, an MDM2 antagonist, in patients with advanced solid tumors
Amita Patnaik et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2015)
Drugging the p53 pathway: understanding the route to clinical efficacy (vol 13, pg 217, 2014)
Kian Hoe Khoo et al.
NATURE REVIEWS DRUG DISCOVERY (2014)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition
Sanjeev Shangary et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Critical aspects of the Bayesian approach to phase I cancer trials
Beat Neuenschwander et al.
STATISTICS IN MEDICINE (2008)
MDM2 inhibitors for cancer therapy
Lyubomir T. Vassilev
TRENDS IN MOLECULAR MEDICINE (2007)
In vivo activation of the p53 pathway by small-molecule antagonists of MDM2
LT Vassilev et al.
SCIENCE (2004)
Share Paper
